Article Text

Download PDFPDF
Paediatric xenotransplantation clinical trials and the right to withdraw
  1. Daniel J Hurst1,
  2. Luz A Padilla2,
  3. Wendy Walters3,
  4. James M Hunter4,
  5. David K C Cooper5,
  6. Devin M Eckhoff6,
  7. David Cleveland7,
  8. Wayne Paris8
  1. 1Family & Community Medicine, UAB, Birmingham, Alabama, USA
  2. 2Epidemiology, UAB, Birmingham, Alabama, USA
  3. 3Clinical Ethics, UAB, Birmingham, Alabama, USA
  4. 4Anesthesiology and Critical Care, UAB, Birmingham, Alabama, USA
  5. 5Co-Director, UAB Xenotransplant Program, UAB, Birmingham, Alabama, USA
  6. 6Director, Division of Transplantation, UAB, Birmingham, Alabama, USA
  7. 7Surgery, UAB, Birmingham, Alabama, USA
  8. 8Social Work, Abilene Christian University, Abilene, Texas, USA
  1. Correspondence to Dr Daniel J Hurst, Family & Community Medicine, UAB, Birmingham, AL 35042, USA; djhurst{at}uab.edu

Abstract

Clinical trials of xenotransplantation (XTx) may begin early in the next decade, with kidneys from genetically modified pigs transplanted into adult humans. If successful, transplanting pig hearts into children with advanced heart failure may be the next step. Typically, clinical trials have a specified end date, and participants are aware of the amount of time they will be in the study. This is not so with XTx. The current ethical consensus is that XTx recipients must consent to lifelong monitoring. While this presents challenges to the right to withdraw in the adult population, additional and unanswered questions also linger in the paediatric population. In paediatric XTx, parents or guardians consent not only to the initial treatment of the child but also to lifelong monitoring, thus making a decision whose consequences will remain present as the child develops the capacity for assent, and finally the capacity for informed consent or refusal. This article presents and evaluates unanswered paediatric ethical questions in regard to the right to withdraw from XTx follow-up in the paediatric population.

  • ethics
  • public health ethics
  • research ethics
  • research on special populations
  • transplantation
View Full Text

Statistics from Altmetric.com

Footnotes

  • Twitter @hurstdanielj

  • Contributors DJH: primary author. DJH/LAP/WP: designed the paper. WW/JMH: provided key ethical opinion. DME/DC/DKCC: provided key xenotransplant and surgical perspective.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.